Access Pharmaceuticals Inc. (OTC Bulletin Board:AXCS)
Aphthasol (amlexanox oral paste 5% for treating aphthous ulcers; FDA-approved)
Block Drug Co. (NASDAQ:BLOCA)
Access licensed marketing rights to product for all markets except U.S., Japan and Israel; Access will share in international product revenues and assume international responsibility for sublicensing, regulatory approvals and new product development; parties will share certain regulatory and development costs (6/98)
Access Pharmaceuticals Inc. (OTC Bulletin Board:AXCS)
Aphthasol (amlexanox oral paste 5% for treating aphthous ulcers; FDA-approved)
Laboratorios Dr. Esteve SA (Spain)
Letter of intent to license product for marketing in Italy, Spain, Portugal and Greece; Access gets upfront license fee, milestones and royalties (10/98)
Access Pharmaceuticals Inc. (OTC Bulletin Board:AXCS)
Aphthasol (amlexanox oral paste 5% for treating aphthous ulcers; FDA-approved)
Meda AB (Sweden)
Letter of intent to license product for marketing in Sweden, Finland, Norway, Denmark, Latvia, Estonia, Lithuania and Iceland; Access gets upfront license fee, milestones and royalties (10/98)
Access Pharmaceuticals Inc. (OTC Bulletin Board:AXCS)
Aphthasol (amlexanox oral paste 5% for treating aphthous ulcers; FDA-approved)
Paladin Labs Inc. (subsidiary of Pharmascience; Canada)
Letter of intent to license product for marketing in Canada; Paladin will be responsible for obtaining regulatory approval in Canada; Access gets milestones and royalties (8/98)
Access Pharmaceuticals Inc. (OTC Bulletin Board:AXCS)
Aphthasol (amlexanox oral paste 5% for treating aphthous ulcers; FDA-approved)
Strakan Ltd. (U.K.)
Letter of intent to license product for marketing in U.K. and Ireland; Strakan will be responsible for obtaining regulatory approvals in U.K. and European Community; Access gets milestones and royalties (7/98)
Affymetrix Inc.
Development of Gene-Array scanner to read DNA probe arrays
Hewlett-Packard Co. (NYSE:HWP)
Extension of 2/97 manufacturing agreement; Hewlett-Packard will continue to make confocal lasers to be sold as part of Affymetrix¿s GeneChip system through 2002 (8/98)
AltaRex Corp. (Canada)
Ovarex therapeutic vaccine for delaying time to relapse in ovarian cancer patients and for improving survival in these patients (based on anti-idiotype induction therapy; 2 Phase II/III North American clinical trials ongoing)
Medac GmbH (Germany)
AltaRex reacquired marketing rights in Western Europe from Medac; AltaRex decided to terminate all European clinical trials for the present because it is conducting 2 parallel trials in North America (1/98)
Alza Corp.
Ditropan (oxybutynin chloride) for treating urge urinary incontinence (Alza submitted NDA in 12/97 on an OROS controlled-release formulation of product, Ditropan XL)
Procter & Gamble Pharmaceuticals Canada (subsidiary of The Procter & Gamble Co.; NYSE: PG) and Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany)
Alza acquired Canadian marketing rights and also acquired right to use Ditropan trademark in Canada with other Alza products; Hoechst Marion Roussel will manufacture and package product; Alza will submit marketing application for Ditropan XL in Canada (4/98)
American Biogenetic Sciences Inc.
Thrombus precursor protein (TpP) diagnostic kit; immunoassay that measures soluble fibrin; for diagnosing blood clot formation
Corgenix Medical Corp. (OTC Bulletin Board:COGX)
Corgenix will distribute product in North America and will collect and share clinical data with American Biogenetic Sciences (8/98)
American Biogenetic Sciences Inc.
Thrombus precursor protein (TpP) diagnostic kit; immunoassay that measures soluble fibrin; for diagnosing blood clot formation
Shield Diagnostics Ltd.(U.K.)
Shield will distribute product in U.K. (4/98)
Anesta Corp.
Product line of oral transmucosal fentanyl products, including Actiq (for treating breakthrough pain in cancer patients)
Grupo Ferrer (Spain)
Ferrer has exclusive right to market, sell and distribute products in Spain and Portugal (1/98)
Anesta Corp.
Product line of oral transmucosal fentanyl products, including Actiq (for treating breakthrough pain in cancer patients)
Laboratoire L. Lafon (France)
Lafon has exclusive right to market, sell and distribute products in France (6/98)
Anika Therapeutics Inc. (NASDAQ:ANIK)
Orthovisc (hyaluronic acid) for treating osteoarthritis of the knee (FDA accepted PMA for filing 2/98)
Zimmer Inc. (subsidiary of Bristol-Myers Squibb Co.; NYSE: BMY)
Expansion of 11/97 marketing agreement to include sales, marketing and distribution in Europe, Scandinavia and Latin America; Anika gets $3.5M in licensing fees, including $1.5M upfront (6/98)
Aronex Pharmaceuticals Inc.
Nyotran (liposomal formulation of Nystatin) for treating systemic fungal infections (currently in pivotal Phase III trials)
Abbott Laboratories (NYSE:ABT)
Abbott gets worldwide marketing rights; Aronex gets $40M total ($2.85M upfront, $3M in equity purchase [0.84M shares], milestones and development support); Aronex also gets royalties; Abbott will fund continued clinical development; Aronex has option to co-promote in U.S. and Canada for at least 2 years; Abbott responsible for product registration outside U.S.; Abbott has manufacturing option (11/98)
Athena Neurosciences Inc. (wholly owned subsidiary of Elan Corp. plc; Ireland)
Wyeth-Ayerst¿s product Mysoline (primidone; anticonvulsant for treating epilepsy and seizure disorders)
Wyeth-Ayerst Laboratories (division of American Home Products Corp.; NYSE: AHP)
Elan acquired exclusive product distribution rights and trademark in U.S. and Canada; agreement subject to clearance by Federal Trade Commission (2/98)
Livingston will warehouse and distribute product if approved by FDA for marketing (11/98)
Aviron
FluMist (nasal spray formulation of influenza vaccine; cold-adapted live virus vaccine)
CSL Ltd. (ASX:CSL; Australia)
CSL gets exclusive rights to market product in Australia, New Zealand and certain other South Pacific countries; companies will jointly conduct clinical trials in Australia; companies will share profits; Aviron has option to get warrants for CSL common stock on achievement of milestones (6/98)
Bio-Technology General Corp.
BioLon (1% solution of sodium hyaluronate) for use in ophthalmic surgical procedures (i.e., cataract removal)
Akorn Inc. (NASDAQ:AKRN)
Akorn gets license to distribute and market product in U.S. (4/98)
Bio-Technology General Corp.
GrowJect Injectable (recombinant human growth hormone)
JCR is Bio-Technology General¿s Japanese licensee for this product; JCR will supply Sumitomo with product which Sumitomo will distribute in Japan beginning in 1/99 (following the termination of its distribution agreement for Pharmacia & Upjohn Inc.¿s Genotropin at the end of 1998) (1/98)
Bio-Technology General Corp.
Serono¿s line of pediatric growth products: Saizen (recombinant human growth hormone for treating growth hormone deficiency in children); Geref (growth hormone releasing hormone for treating idiopathic growth hormone deficiency in children); and Geref Diagnostic (for diagnosing growth disorders)
Serono Laboratories Inc. (member of the Ares-Serono Group; Switzerland)
Bio-Technology General will co-market products in U.S. and get share of revenues; further details ND (5/98)
Biomatrix Inc.
Synvisc (elasto-viscous hylan biopolymer for treating osteoarthritis of knee; FDA approved 8/97)
Novartis Pharma AG (Switzerland)
Novartis gets exclusive marketing and distribution rights in Mexico, Central America, South America and the Caribbean; Biomatrix gets $3.5M in fees; Novartis responsible for marketing approvals in its territories; Novartis will also conduct post-marketing clinical trials in Mexico, Argentina and Brazil (3/98)
Biora AB (Sweden)
Emdogain (gel formulation containing a porcine potein that mimics human protein amellogenin) for periodontal flap surgery
Seikagaku Corp. (Japan)
Expansion of marketing agreement; Seikagaku entered agreement with Yoshida Dental Trade to broaden product¿s penetration of Japanese market (12/98)
Biota Holdings Ltd. (ASX:BTA; Australia)
Biota¿s AB FLU OIA (optical immunoassay; rapid point-of-care diagnostic test for influenza strains A and B as well as variants)
PanBio Pty Ltd. (Australia)
PanBio will market and distribute product in Australia; Biota retains worldwide marketing rights outside Australia and U.S. (5/98)
BioTime Inc.
Hextend (synthetic blood plasma volume expander) to replace blood lost in surgery or trauma (NDA submitted 12/97)
Nihon Pharmaceutical Co. Ltd. (Japan)
Letter of intent to negotiate licensing agreement for Nihon to manufacture and market product in Japan (1/98)
Cangene Corp.
WinRho SDF (hyperimmune product for preventing hemolytic disease in newborns)
CSL Ltd. (ASX:CSL; Australia)
5-year exclusive agreement with optional 2-year extension; CSL will distribute product in Australia; companies will work together toward product approval in Australia; CSL has guaranteed purchase of specified minimum quantities (9/98)
Celgene Corp.
Celgene¿s chirally pure version of Ritalin for treating children with attention deficit hyper-activity disorder
Biovail Corp. International (TSE:BVF; Canada)
Biovail gets exclusive marketing rights in Canada; Biovail will buy $2.5M in Celgene stock at 25% premium to market; Celgene gets licensing fees and royalties (6/98)
Cellomics Inc.*
Integrated systems and services for drug discovery process (combines Cellomics¿ high-content screening systems with Zeiss¿ ultra-high throughput screening system)
Carl Zeiss Jena GmbH (Germany)
Exclusive worldwide co-marketing, manufacturing and sales agreement on combined products and services (4/98)
Termination of co-promotion agreement on Retevase (DuPont had pre-existing contract with Roche Holding Ltd., from which Centocor bought Retevase in 3/98; see below); Centocor now has exclusive rights to market product in U.S., beginning 1/1/99 (12/98)
Roche Healthcare Ltd. (affiliate of Roche Holding Ltd.; Switzerland)
As part of its purchase of Corange Ltd. (the parent company of Boehringer Mannheim GmbH, the manufacturer and marketer of Retevase), the Federal Trade Commission required Roche to divest Retevase; Centocor paid $335M cash for the U.S. and Canadian rights to the product (including intellectual property and various marketing assets) (definitive agreement 2/98; finalized 3/98)
Centocor Inc.
Avakine (infliximab; chimeric monoclonal antibody to tumor necrosis factor alpha) for treating Crohn¿s disease (MAA submitted in Europe 3/98; FDA advisory panel recommended approval 5/98) and rheumatoid arthritis (Phase III trial ongoing)
Schering-Plough Corp. (NYSE:SGP)
Schering-Plough gets exclusive marketing rights worldwide except in U.S., Japan and parts of the Far East; Centocor gets $20M upfront and $30M in milestones tied to international approvals; companies will divide profits on sales and share certain development expenses; Centocor retains U.S. marketing rights for all indications; Centocor retains right to co-promote (4/98)
Cephalon Inc.
Provigil (modafinil; oral formulation of synthetic compound thought to affect alpha-adrenergic receptors in the brain) for treating narcolepsy; also Myotrophin (recombinant human insulin-like growth factor) for treating amyotrophic lateral sclerosis
Dompe SpA (Italy)
Dompe will market, sell and distribute products in Italy; terms ND (6/98)
Cephalon Inc.
Aguettant¿s Apokinon (apomorphine HCl) for treating Parkinson¿s disease
Laboratoire Aguettant SA (France)
Cephalon¿s U.K. subsidiary has 10-year agreement to market product in France; further details ND (1/98)
Cephalon Inc.
Medtronic¿s intrathecal baclofen therapy for intractable spasticity
Medtronic Inc. (NYSE:MDT)
Renewal of co-promotion agreement; Cephalon will co-promote product through 4/99 to neurologists and physiatrists in U.S. (7/98)
Cephalon Inc.
Provigil (modafinil; oral formulation of synthetic compound thought to affect alpha-adrenergic receptors in the brain) for treating narcolepsy
Merckle GmbH (Germany)
Cephalon U.K. Ltd. licensed exclusive rights to promote product in Austria and Switzerland in a 10-year agreement (12/98)
Cephalon Inc.
Provigil (modafinil; oral formulation of synthetic compound thought to affect alpha-adrenergic receptors in the brain) for treating narcolepsy
Nippon Shoji Kaisha Ltd. (Japan)
Nippon Shoji will develop and market product in Japan; Cephalon gets milestones and royalties (6/98)
Cephalon Inc.
Zeneca¿s Zomig (oral treatment for migraine)
Zeneca Group plc (NYSE:ZEN; U.K.)
Cephalon U.K. Ltd. will co-promote product in U.K. (12/98)
Chiron Corp.
Rabipur (cell culture-based rabies vaccine) and other vaccines
Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany)
Formation of joint venture in India, to be called Chiron Behring Vaccines Private Ltd. and owned 51% by Chiron and 49% by Hoechst Marion Roussel; joint venture will manufacture Rabipur and other vaccines; Hoechst Marion Roussel will market products in India, Nepal, Sri Lanka, and Bangladesh; Chiron will market in rest of world; Hoechst Marion Roussel will also market certain other Chiron vaccines, including for hepatitis A virus infection (5/98)
Chiroscience Group plc (U.K.)
Chirocaine (long-acting local anesthetic that contains levobupivacaine) for use in wide range of surgical procedures
Zeneca Group plc (NYSE:ZEN; U.K.)
Zeneca gets exclusive license to market product worldwide, except Japan; Chiroscience responsible for registering product in Europe and U.S.; Zeneca will take on all further marketing responsibilities and fund Phase IIIb/IV trial as well as register product in remaining territories; Zeneca gets exclusive rights to Chirocaine trademark; Chiroscience retains right to manufacture active ingredient; Chiroscience retains rights in Japan and rights to other uses of levobupivacaine; Chiroscience gets royalties on Zeneca¿s sales; separately, Zeneca bought 3.5M shares of Chiroscience at $7.12 each for $25.1M total (3.17% equity stake (3/98)
CollaGenex Pharmaceuticals Inc.
Periostat (oral drug consisting of sub-antibiotic dose of doxycycline) for periodontal disease
Applied Analytical Industries Inc. (NASDAQ:AAII)
Applied Analytical will manufacture product for sale in U.S. (6/98)
CollaGenex Pharmaceuticals Inc.
Periostat (oral drug consisting of sub-antibiotic dose of doxycycline) for periodontal disease
Laboratoires Pharmascience (subsidiary of Groupe Expanscience; France)
Pharmascience gets exclusive license to market product in France and certain related territories; CollaGenex gets upfront fee, milestones and royalties (8/98)
CollaGenex Pharmaceuticals Inc.
SmithKline¿s Denavir (penciclovir cream) for treating recurrent cold sores in adults
CollaGenex will co-promote product to dental community in U.S. (10/98)
Cortecs plc (U.K.)
Macritonin (oral formulation of salmon calcitonin) for treating post-menopausal osteoporosis
Ferrer Internacional SA (Spain)
Ferrer will distribute product in Latin America; it gets semi-exclusive rights in Brazil and Argentina and exclusive rights elsewhere except Mexico; agreement also includes the Philippines; Ferrer responsible for regulatory approvals; Cortecs will manufacture and sell product to Ferrer; Cortecs gets royalties (8/98)
Cortecs plc (U.K.)
Macritonin (oral formulation of salmon calcitonin) for treating post-menopausal osteoporosis
Glaxo Wellcome AEBE (Greece; unit of Glaxo Wellcome plc; NYSE: GLX; U.K.)
Glaxo will distribute product in Greece; Cortecs gets milestones and sales minima of $14M; Glaxo will participate in registration process in Greece (Cortecs submitted marketing application in 10/97); Cortecs will manufacture and supply product (5/98)
Cortecs Diagnostics Ltd. (subsidiary of Cortecs plc; U.K.)
Helisal OneStep rapid test (for detecting Helicobacter pylori infection) and Link2 infectious mononucleosis rapid test (point-of-care)
Becton Dickinson & Co. (NYSE:BDX)
Becton Dickinson will distribute products in U.S.; agreement allows for addition of other territories; companies will collaborate to develop other products using Cortecs¿ one-step technology (6/98)
Cortecs Diagnostics Ltd. (subsidiary of Cortecs plc; U.K.)
Helisal OneStep (rapid point-of-care assay for Helicobacter pylori infection)
Boehringer Mannheim GmbH (Germany)
New distribution agreement that replaces former exclusive rights held by Boehringer with non-exclusive rights to distribute product outside Japan (6/98)
Coulter Pharmaceutical Inc.
Bexxar (131-I-labeled murine monoclonal antibody against CD20 antigen on B cells) for treating non-Hodgkin¿s lymphoma (pivotal trials completed)
SmithKline Beecham plc (NYSE:SBH; U.K.)
Potential value to Coulter is $132M, plus shared profits and royalties; companies will jointly market product in U.S. and share profits equally; SmithKline gets exclusive rights outside U.S., except in Japan; Coulter gets royalties; SmithKline gets access to 2nd-generation anti-CD20 compounds; Coulter gets upfront payment of $41.5M (including $7.25M in equity), a $15M credit line, and $76M in regulatory and marketing milestones in other areas of world (12/98)
Cygnus Inc.
GlucoWatch (non-invasive, continuous glucose monitoring device for management of diabetes)
Becton Dickinson & Co. (NYSE:BDX)
Termination of 2/96 marketing and distribution agreement, based on re-evaluation by both companies of long-range business strategies and consideration of changes in diabetes monitoring arena that have occurred since original agreement signed (3/98)
Cytogen Corp.
Quadramet (samarium-153-EDTMP; isotope concentrates in areas of new bone formation) for treating pain associated with cancer that has spread to bone (FDA-approved 3/97)
Berlex Laboratories Inc. (subsidiary of Schering AG; Germany)
Marketing agreement; Berlex gets exclusive license to sell product in North and South America; Cytogen gets $8M upfront on completion of supply agreement with DuPont (see below), of which it will pay $4M to DuPont; Cytogen also gets royalties on net sales and milestones on preset sales levels; Cytogen will complete Phase IV trials specified by FDA; Berlex will fund clinical programs aimed at expanding current and additional product indications (10/98)
Cytogen Corp.
Quadramet (samarium-153-EDTMP; isotope concentrates in areas of new bone formation) for treating pain associated with cancer that has spread to bone (FDA approved 3/97)
Berlex Laboratories Inc. (subsidiary of Schering AG; Germany) and DuPont Pharmaceuticals Co. (NYSE:DD)
DuPont will supply product for 5 years as well as continue to manufacture and distribute it; DuPont received $4M to secure long-term supply agreement (11/98)
Cytogen Corp.
Quadramet (samarium-153-EDTMP; isotope concentrates in areas of new bone formation) for treating rheumatoid arthritis (currently in Phase I trial)
The Dow Chemical Co. (NYSE:DOW)
Companies expanded 5/93 licensing agreement; Cytogen, which previously had rights for this use in North and South America only, now gains additional territories, including Europe and Japan; Berlex Laboratories Inc., which will market product (see above) also holds license for these territories (12/98)
Cytogen Corp.
Quadramet (samarium-153-EDTMP; isotope concentrates in areas of new bone formation) for treating pain associated with cancer that has spread to bone (FDA approved 3/97)
The DuPont Merck Pharmaceutical Co. (was joint venture, but in 5/98 DuPont agreed to pay $2.6B to buy out Merck¿s half interest)
Termination of12/94 licensing agreement for DuPont Merck to market product in U.S.; in 5/98, parties accused each other of breach of agreement, but by 6/98 the agreement had been terminated; DuPont Merck has initiated efforts to find new marketing partner for Cytogen; DuPont Merck paid Cytogen $3.8M and will manufacture product over next 2 years; Cytogen will begin marketing directly to cancer centers (5/98; 6/98)
CytRx Corp.
Flocor (purified poloxamer 188; surfactant) for improving blood flow in ischemic tissue
Abbott Laboratories (NYSE:ABT)
Abbott will manufacture Flocor on commercial scale; Abbott will sterile-fill Flocor for CytRx and will manage its part of the chemistry, manufacturing and controls section of planned NDA filing (4/98)
Dendreon Corp.*
DACS 300 System (facilitates preparation of CD34 positive cells from peripheral blood)
Fresenius Critical Care International (unit of Fresenius AG; Germany)
Fresenius will market and distribute product worldwide (4/98)
Draxis Health Inc. (Canada)
Lilly¿s drug Permax (pergolide mesylate, a D1 and D2 dopamine receptor agonist) for treating Parkinson¿s disease
Eli Lilly Canada Inc. (unit of Eli Lilly and Co.; NYSE:LLY)
Draxis renewed its 1994 agreement to exclusively market drug in Canada; Lilly will manufacture product and supply it to Draxis exclusively for marketing and distribution in Canada; terms for 10 years with automatic yearly renewals thereafter; Draxis will make fixed payments to Lilly of $6M over 5 years plus additional variable payments (5/98)
Enzon Inc.
Oncaspar (native Lasparaginase modified with polyethylene glycol) for treating acute lymphoblastic leukemia
Rhone-Poulenc Rorer Inc. (subsidiary of Rhone-Poulenc Group; France)
Expansion of 12/93 marketing agreement; Rhone-Poulenc Rorer will now market product in Pacific Rim (as well as other territories) (5/98)
Epitope Inc.
OraSure oral specimen collection device
STC Technologies Inc.*
5-year agreement; Epitope will be exclusive supplier of device for use with STC¿s lab-based tests for drugs-of-abuse for sale in U.S. and Europe (excluding U.K. and Ireland); STC will be exclusive distributor in same territories; Epitope will sell devices to STC and gets a percentage of gross revenues (11/98)
Genelabs Technologies Inc.
Vaccine for hepatitis E virus infection
SmithKline Beecham plc (NYSE:SBH; U.K.)
Expansion of SmithKline¿s marketing rights to product (from 9/92 agreement); SmithKline gets exclusive (rather than co-exclusive) rights in Asia; Genelabs gets $1M payment; other terms remain unchanged (9/98)
Genentech Inc.
Herceptin (humanized monoclonal antibody to HER2 growth factor receptor) for treating HER2-overexpressing metastatic breast cancer
Hoffmann-La Roche Ltd. (Switzerland)
Roche gets exclusive marketing rights outside U.S.; Genentech gets ¿substantial¿ up-front fee, milestones and royalties; companies will contribute equally to global development costs; agreement includes joint global development of product for treating other solid tumors (7/98)
Genentech Inc.
Recombinant human growth hormone (hGH) products Nutropin AQ (FDA-approved) and ProLease hGH (sustained release formulation of hGH, employs Alkermes Inc.¿s drug delivery technology; currently in U.S. Phase III trials for growth hormone-deficient children)
Sumitomo Pharmaceuticals Co. Ltd. (Japan)
Sumitomo gets exclusive rights to develop, import and distribute both products in Japan; Genentech got large upfront payment and also gets milestones; Genentech and Alkermes will manufacture products for sale to Sumitomo (1/98)
Genetic Micro-Systems Inc.*
Instrumentation for DNA microarrays
Takara Shuzo Co. Ltd. (Japan)
Takara gets exclusive rights to distribute instrumentation in Japan, China, Taiwan and Korea; Takara also gets exclusive rights to use technology to manufacture DNA chips; Genetic MicroSystems gets milestones and royalties and an equity investment from Takara (9/98)
Genzyme Corp.
Thyrogen (recombinant human thyroid stimulating hormone) for use in monitoring recurrence of thyroid cancer
Knoll Pharmaceutical Co.
5-year exclusive agreement to jointly market product in U.S.; Genzyme gets upfront payment (8/98)
Guilford Pharmaceuticals Inc.
Gliadel wafer (biodegradable polymer containing carmustine) for treating brain cancer
Rhone-Poulenc Rorer Inc. (subsidiary of Rhone-Poulenc SA; NYSE:RP; France)
Amendment of 6/96 marketing, sales and distribution agreement; companies will now share costs of single multinational Phase III trial of product for use in 1st-line therapy for brain cancer (originally, each firm was to conduct and pay for its own Phase III trial); Guilford will not pay more than $3M aggregate; Japanese rights have reverted back to Guilford; companies have also redefined international regulatory milestones (9/98)
Altana Inc. (subsidiary of Byk Gulden Lomberg Chemische Fabrik GmbH; Germany)
Agreement in principle for Altana to get worldwide marketing rights (except where already licensed); Hyal gets upfront fee and royalties; companies will also jointly develop Hyanalgese-D for uses other than pain of osteoarthritis (7/98)
Fujisawa Healthcare Inc. (U.S.; subsidiary of Fujisawa Pharmaceutical Co. Ltd.; Japan)
Letter of intent to license exclusive rights in U.S., Canada and Mexico to Fujisawa; Fujisawa paid $0.25M for 90-day period of exclusivity on option; if deal is finalized, Hyal gets milestones and royalties (12/98)
ID Biomedical Corp. (Canada)
ID Biomedical¿s gene-based tests for detecting methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus
Mitsubishi Chemical Corp. (Japan)
Memorandum of intent; Mitsubishi will be exclusive distributor in Japan (7/98)
Immunex Corp.
Nuvance (soluble interleukin-4 [IL-4] receptor) plus 3 other soluble receptors (IL-1 receptor types 1 and 2 and IL-7 receptor)
Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany)
Immunex acquired product rights outside North America (it already held North American rights to all 4 molecules from a 1990 agreement between the parties); Immunex will pay Hoechst Marion Roussel a 1-time fee of $10M as well as royalties on product sales (4/98)
Immunex Corp.
Immunex¿s generic paclitaxel (extracted from all parts of cultivars of Pacific yew trees) and IVX¿s branded paclitaxel Paxene (extracted from needles and limb stock of ornamental yew trees), both for treating various cancers
IVX BioScience Inc. (formerly IVAX Corp.; AMEX:IVX)
Companies will collaborate to market each other¿s paclitaxel products in U.S.; IVX acquired Immunex¿s ANDA for paclitaxel (submitted 8/97) in exchange for unspecified cash payment; IVX will also acquire Immunex¿s inventories of bulk product; if FDA approves Immunex¿s ANDA, it gets royalties on sales; Immunex will promote IVX¿s Paxene (if FDA-approved) and will earn fees on product sales; transaction subject to anti-trust considerations (6/98)
Immunomedics Inc.
CEA-Scan (radiolabeled monoclonal antibody-based in vivo diagnostic imaging agent for colorectal cancer)
Bergen Brunswick will distribute product in U.S. after the Mallinckrodt agreement terminates in 4/98 (see below) (3/98)
Immunomedics Inc.
CEA-Scan (radiolabeled monoclonal antibody-based in vivo diagnostic imaging agent for colorectal cancer)
Mallinckrodt Group Inc. (NYSE:MKG)
Termination of marketing and distribution agreements in Europe (from 3/95) and U.S. (from 4/96); Immunomedics said its decision was strategic; Eli Lilly and Co. (which agreed in 12/97 to distribute Immunomedics¿ infectious disease imaging agent LeukoScan in Europe) will handle distribution of CEA-Scan, as well (2/98)
Immunomedics Inc.
CEA-Scan (radiolabeled monoclonal antibody-based in vivo diagnostic imaging agent for colorectal cancer)
Syncor International Inc. (NASDAQ: SCOR)
Syncor will distribute product in U.S. (9/98)
Integra LifeSciences Corp.
Two products used in surgical procedures to control bleeding (Helistat and Helitene, both made of absorbable collagen)
Century Medical Inc. (wholly owned subsidiary of Itochu Corp.; Japan)
Century Medical gets rights to distribute products in Japan; further details ND (1/98)
Integra LifeSciences Corp.
Two neurosurgery products: dural regeneration device (collagen-based matrix) and peripheral nerve regeneration conduit (thin collagen tube)
Century Medical Inc. (wholly owned subsidiary of Itochu Corp.; Japan)
This is 3rd agreement between companies; Century Medical gets rights to distribute products in Japan; Integra gets upfront fee of $1M in 1Q:98; Century will buy $4M of Integra preferred stock (0.5M shares) in 2Q:98; Century Medical will fund all costs of product development and approval in Japan; 7-year distribution rights begin on day of product approval in Japan (3/98)
Integra LifeSciences Corp.
Absorbable collagen-based matrices for use in periodontics and dental surgery
Sulzer Calcitek Inc. (unit of Sulzer Medica; NYSE:SM)
Expansion of product alliance; Sulzer has been exclusive distributor of Integra¿s dental surgery product line since 1992; alliance extended for 5 years and expanded to include development of Integra¿s Biomend collagen matrix for guided tissue regeneration in periodontal surgery; Sulzer will fund development work (11/98)
Interneuron Pharmaceuticals Inc.
Oral citicholine for protecting brain tissue from cerebral infarction following ischemic stroke
Ferrer Internacional SA (Spain)
Ferrer gets worldwide license (except in U.S. and Canada) to Interneuron¿s patent rights relating to this indication for the product; Interneuron gets royalties (7/98)
Isis Pharmaceuticals Inc.
Antisense oligonucleotides
Zeneca LifeScience Molecules (division of Zeneca Group plc; NYSE:ZEN; U.K.)
Five-year contract; Zeneca will manufacture antisense oligonucleotides for use in Isis¿ clinical trials and for sale to 3rd parties; financial terms ND (3/98)
The Liposome Co. Inc.
Astra¿s MVI-12 unit vial (injectable multivitamin product used by severely ill hospitalized patients in need of nutritional supplements)
Astra USA Inc. (subsidiary of Astra AB; Sweden)
3-year agreement; The Liposome Co. will manufacture Astra¿s product; Astra will supply bulk product and will market finished product; financial terms ND (4/98)
The Liposome Co. Inc.
Abelcet (amphotericin B lipid complex) for treating severe systemic fungal infections
Wyeth-Ayerst International Inc. (division of American Home Products Corp.; NYSE:AHP)
Wyeth-Ayerst will market product in Austria (already markets Abelcet in France, Italy, Sweden, Finland, Norway, Denmark and Iceland) (4/98)
The Liposome Co. Inc.
Abelcet (amphotericin B lipid complex) as 1st-line therapy for cryptococcal meningitis and 2nd-line therapy for severe systemic fungal infections
Wyeth-Ayerst International Inc. (division of American Home Products Corp.; NYSE:AHP)
Wyeth-Ayerst will market product in Greece (7/98)
Matritech Inc.
NMP22 test kit for management of patients with bladder cancer (enzyme immunoassay that measures cancer-specific nuclear matrix protein antigens in urine; FDA approved 7/96)
Curtin Matheson Scientific/Fisher Health-Care (division of Fisher Scientific International Inc.)
Curtin Matheson will distribute product in U.S. (3/98)
Matritech Inc.
NMP22 test kit for management of patients with bladder cancer (enzyme immunoassay that measures cancer-specific nuclear matrix protein antigens in urine; FDA approved 7/96)
Laboratory Corporation of America Holdings (NYSE:LH)
Companies will co-market product in U.S. (9/98)
Matritech Inc.
NMP22 test kit for management of patients with bladder cancer (enzyme immunoassay that measures cancer-specific nuclear matrix protein antigens in urine; FDA approved 7/96)
Organon Teknika Espanola SA (Spain; unit of Akzo Nobel NV; the Netherlands)
Marketing and distribution in Spain and Portugal (4/98)
Megabios Corp.
DNA plasmids and lipid:DNA complexes
DSM Biologics (Gist-Brocades/Bio-Intermediair; the Netherlands)
Companies will work together to create facility for contract manufacturing of DNA plasmids and lipid: DNA complexes for the gene therapy industry; Megabios licensed its manufacturing technology to DSM; Megabios gets license fee and milestones; 3-year exclusive partnership (9/98)
Molecular Biosystems Inc.
Ultrasound contrast imaging agents FS069 (2nd-generation cardiac imaging agent) and Oralex (oral imaging agent for upper gastrointestinal tract)
Chugai Pharmaceuticals Ltd. (Japan)
Chugai gets exclusive license to market products in Japan, Taiwan and South Korea; Molecular Biosystems gets $14M upfront license fee and $20M in milestones; Chugai will buy undisclosed equity stake in Molecular Biosystems and pay royalties on product sales (4/98)
Neoprobe Corp.
Neoprobe¿s gamma detection products for use in intraoperative lymphatic mapping
CEI Ltda. (Brazil) and Evergreen Enterprises Ltd. (People¿s Republic of China)
Partners get rights to distribute products in South America and China, respectively; both distributors will register products in respective territories (10/98)
Neoprobe Corp.
Gamma-guided surgery products (portable radioisotope detector and 14mm and 19mm reusable probes for gamma-guided lymphatic mapping and minimally invasive surgery for cancer)
Ethicon Endo-Surgery Inc. (a Johnson & Johnson company; NYSE: JNJ)
Agreement has initial term of 1 year; Ethicon will promote and sell products as well as train physicians in use of device; its initial territory is U.S., but expansion to Europe, Japan and Australia is planned (4/98)
Neose Technologies Inc.
Use of Neose¿s multi-transferase reaction technology to produce complex carbohydrates in large quantities
Bristol-Myers Squibb Co. (NYSE:BMY)
Neose will manufacture complex carbohydrates for 2 oncology vaccines being developed by Bristol-Myers; further details ND (6/98)
Neurex Corp.
Corlopam (dopamine receptor agonist that causes dilation of blood vessels) for treating short-term hypertension (FDA approved 9/97)
Crystaal Corp. (subsidiary of Biovail Corp.; TSE: BVF; Canada)
Crystaal will obtain regulatory approval for drug and market it in Canada (4/98)
Penederm Inc.
Alpharma¿s permethrin cream 5% (topical treatment of scabies infection; FDA approved 1/98)
Alpharma Inc. (NYSE:ALO)
Penederm will market product in U.S. under its Acticin brand name; Alpharma will manufacture and supply product to Penederm; Alpharma gets milestones and royalties (1/98)
Penederm Inc.
Topical drug Mentax (butenafine HCl 1% antifungal cream) for treating athlete¿s foot
Pedinol Pharmacal Inc.
Pedinol will promote product to podiatrists in U.S.; companies will share profits (7/98)
Phyton Inc.*
Use of Phyton¿s plant cell fermentation technology for commercial-scale manufacturing of paclitaxel (active ingredient in Bristol-Myer¿s FDA-approved anti-cancer product Taxol)
Bristol-Myers Squibb Co. (NYSE:BMY)
Companies have been collaborating on commercial plant cell fermentation technology since 1993; Phyton granted Bristol-Myers an exclusive license in 1995; now the companies intend to develop manufacturing process for paclitaxel; Phyton gets funding, milestones and royalties (6/98)
Qiagen NV (the Netherlands)
Nucleic acid sample purification and preparation products (for use in Abbott¿s molecular diagnostics)
Abbott Laboratories (NYSE:ABT)
5-year supply agreement; Qiagen will supply Abbott with its products, which Abbott will adapt for use in its LCx probe-based diagnostic system; Qiagen retains rights to market products in all other formats (10/98)
Qiagen NV (the Netherlands)
Organon¿s NASBA technology (nucleic acid sequence-based amplification) for research purposes
Organon Teknika (Belgium; unit of Akzo Nobel NV; the Netherlands)
Qiagen gets non-exclusive worldwide license to develop, manufacture and market NASBA reagent kits to research market (3/98)
Repligen Corp.
Amersham¿s recombinant Protein A (binds antibodies with high specificity) for use in purification and manufacturing of therapeutic monoclonal antibodies and proteins
Amersham Pharmacia Biotech (joint venture of Nycomed Amersham plc and Pharmacia & Upjohn Inc.)
Repligen will be primary supplier of recombinant Protein A to Amersham Pharmacia Biotech for 10 years; Repligen remains exclusive source of product worldwide and retains all rights to commercialize product for human therapeutics (12/98)
Ribi ImmunoChem Research Inc.
Melacine melanoma vaccine (lysed, purified cells from 2 human melanoma cell lines combined with Detox adjuvant)
Schering-Plough Corp. (NYSE:SGP)
Schering-Plough gets exclusive worldwide rights (except Canada) to distribute, market and sell product; Ribi gets $30M in signing fees and milestones on gaining U.S. and European marketing approvals for Melacine as monotherapy for Stage IV disease; additional milestones on gaining U.S. and European approvals for Melacine as either combination therapy with Intron A for Stage IV disease or as monotherapy for preventing recurrence of Stage II disease; Ribi also gets transfer payments for supplies of Melacine and margins on sales (3/98); agreement amended 6/98, giving Schering-Plough exclusive rights worldwide (adds Canada to its territories) (6/98)
SciClone Pharmaceuticals Inc.
Zadaxin (thymosin alpha 1; synthetic version of naturally occurring hormone thymosin) for use as vaccine adjuvant and for treating non-small-cell lung cancer
Sclavo SpA (Italy)
SciClone acquired marketing approval in Italy for Zadaxin as vaccine adjuvant and marketing application in Italy for non-small-cell lung cancer from Sclavo (to which it had sublicensed those rights in 1997); SciClone also acquired all of Sclavo¿s development and marketing rights in Spain and Portugal; SciClone paid in the aggregate $1.84M for these rights ($0.3M cash; 0.38M shares SciClone stock for $1.54M and 2-year warrants for 0.38M shares SciClone stock) (4/98)
Scios Inc.
Natrecor (genetically engineered version of naturally occurring cardiac hormone human B-type natriuretic peptide) for short-term treatment of congestive heart failure (NDA submitted 4/98)
Bayer AG (Germany)
Bayer gets exclusive worldwide rights to market product; Scios will supply drug to Bayer; Scios will manage Phase IIIb clinical trials; Bayer will manage further worldwide development and commercialization; Scios has option to participate in further drug development; Scios gets $20M upfront cash payment and cash milestones up to $40M total on regulatory approvals in U.S., Europe and Japan; Scios also gets payments for supplying drug; Scios has option to co-promote in U.S. after 3 years (5/98)
Scios Inc.
Janssen¿s anti-psychotic drug Risperdal (risperidone)
Janssen Pharmaceutica NV (Belgium; subsidiary of Johnson & Johnson; NYSE:JNJ)
Scios will co-promote drug; further details ND (5/98)
Scios Inc.
SmithKline¿s Paxil (paroxetine HCl, a selective serotonin reuptake inhibitor) for treating depression and anxiety
SmithKline Beecham plc (NYSE:SBH; U.K.)
Scios will co-promote product in U.S.; further details ND (9/98)
Scios Inc.
Wyeth-Ayerst¿s anti-depressant drug Effexor (venlafaxine HCl; serotonin and norepinephrine reuptake inhibitor)
Wyeth-Ayerst Laboratories (division of American Home Products Corp.; NYSE: AHP)
Termination of 4/96 agreement for Scios to co-promote product in U.S.; agreement terminated by mutual consent (5/98)
Sequus Pharmaceuticals Inc.
Amphocil (a.k.a. Amphotec; lipid-based colloidal dispersion of amphotericin B) for treating systemic fungal infections
Farma-APS Produtos Farmaceuticos Ltd. (Portugal)
Exclusive 5-year agreement for Farma to market, sell and distribute product in Portugal (7/98)
Sequus Pharmaceuticals Inc.
Amphotec (a.k.a. Amphocil; lipid-based colloidal dispersion of amphotericin B) for treating systemic fungal infections
Faulding Pharmaceuticals (division of F.H. Faulding & Co. Ltd.; Australia)
Exclusive 5-year agreement for Faulding to market, sell and distribute product in New Zealand, Australia and Southeast Asia (5/98)
SmithKline gets worldwide marketing rights (except in South Korea); TheraTech gets signing fees, R&D payments, milestones and royalties (2/98)
Unigene Laboratories Inc.
Fortical Injection (recombinant salmon calcitonin) for treating osteoporosis
Tzamal Pharma Ltd. (Israel)
Tzamal gets exclusive license to distribute product in Israel and surrounding area; Unigene gets revenues from sales of finished product to Tzamal; Tzamal will register product and distribute it to managed care and private markets (3/98)
Unimed Pharmaceuticals Inc.
Cryptaz (NTZ; nitazoxanide) for treating Cryptosporidiosis in AIDS
Romark Laboratories
Unimed transferred development and marketing rights, plus associated know-how, to Romark, which now has worldwide marketing rights; Unimed gets upfront payment and royalties on U.S. sales (11/98)
Vanguard Medica Ltd. (U.K.)
Frovatriptan (serotonin 5-hydroxy-tryptamine [5HT] antagonist) for treating migraine
SmithKline Beecham plc (NYSE:SBH; U.K.)
SmithKline Beecham terminated its marketing agreement on the drug; all rights return to Vanguard; SmithKline gets royalties on sales (5/98)
Vion Pharmaceuticals Inc.
Vion¿s Melasyn technology (soluble form of melanin) for use in skin care products and cosmeceuticals
San Mar Laboratories
San Mar gets exclusive worldwide license to manufacture, market and sell products containing Melasyn; Vion gets guaranteed annual royalties over initial 3-year period (2/98)
Viragen Inc.
Omniferon (2nd-generation, multi-species natural alpha interferon derived from human white blood cells)
Southern Health SDN.BHD (Malaysia and Australia)
Southern Health has option to acquire exclusive private-label license to Viragen¿s production process for interferon; Viragen gets $0.2M option fee (option expires 9/30/98); if exercised, Viragen gets upfront license fee of $20M and a continuing 12% royalty; Southern required to begin building at least 1 production facility in its territories (Australia, New Zealand and several Asian countries, but excluding China and Japan) within 1st two years; Southern responsible for funding and conducting clinical trials in its territories (4/98); in 10/98, Southern Health extended its licensing option until 12/31/98 (10/98)
Viragen Europe Ltd. (NASDAQ:VERP; subsidiary of Viragen Inc.)
Omniferon (2nd-generation, multi-species natural alpha interferon) for treating hepatitis B and C virus infections
AGC (Pakistan)
AGC will be exclusive supplier and distributor in Saudi Arabia, Kuwait, Yemen, Oman, United Arab Republic, Brunei and other Middle Eastern countries as well as India and Pakistan; AGC will purchase minimum of $20M in product over 5 years, subject to regulatory approvals in its territories, where it is responsible for clinical and regulatory costs (11/98)
See subscription options